health

Total Investment of Approx. USD 6.8 Million in Product Development for Malaria, NTDs and Other Emerging & Re-emerging Infectious Diseases Such as Ebola Disease

TOKYO, Oct. 29, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.06 billion (USD 6.8 million1) in nine R&D projects for the development of drugs, vaccines and diagnostics for malaria, neglected tropical diseases (NTDs) and emerging & re-emerging infectious diseases such as Ebola disease. 2 Investment of approx. JPY 450 million (USD 2.9 million1) for Clinical...

CityUHK researchers reveal how fructose can suppress liver cancer, opening a new therapeutic avenue

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Fructose is an important nutrient, which despite having a chemical structure very similar to that of glucose, is metabolised very differently in the body. Research into fructose metabolism and its regulation of metabolism in the human body has in recent years become a frontier topic in the life sciences and medicine. A new study led by researchers at City University of Hong Kong (CityUHK) has found that...

CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity

SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced a major clinical validation milestone for CS2009, its investigational PD-1/VEGF/CTLA-4 trispecific antibody, following two Rapid Oral presentations at the European...

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that it has presented the latest clinical results from the Phase II study of...

Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent

FLORENCE, Italy and GAITHERSBURG, Md., Oct. 22, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with Georgiamune Inc., a clinical-stage biotechnology company discovering and developing first-in-class...

New hair transplant review challenges fixed donor limits

MANHATTAN BEACH, Calif., Oct. 22, 2026 /PRNewswire/ -- Dr. U Hair and Skin Clinic in the Los Angeles area reports that a new clinical review led by Sanusi Umar, MD, challenges reliance on fixed maps to define hair transplant donor areas. The open-access paper, "Redefining the Safe Donor Area in Follicular Unit Excision: Toward Dynamic, Patient-Specific Zones," was published Oct. 16 in the Journal of Cosmetic Dermatology.

[China’s Voice] Preclinical Animal Study: Domestic Neurointerventional Robotic System PANVIS STAR® Completes Validation of Five Major Neurointerventional Procedures

SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Neurointerventional robots have long remained at the stage of "only being able to assist with angiography." Through close medical-engineering collaboration with Professor Jianmin Liu's team at Shanghai Changhai Hospital, Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. independently developed a new-generation vascular interventional surgical robot technology and product platform, PANVIS STAR®,...

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 22, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced today that its THERAKOS™ CELLEX™ Photopheresis System has received certification under the EU MDR for an expanded indication. The system is now indicated in Europe for the treatment of immune-related adverse events (irAEs) associated with immune...

Telix Reports Third Quarter 2026 Financial Performance

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026). Q3 2026 Highlights[1]Group revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong...

Patronus Biotech Receives Ethical Approval to Begin First-in-Human Phase 1 Trial of Three Multi-Stage Vaccines Against Malaria in Australia

GUANGZHOU, China, Oct. 20, 2026 /PRNewswire/ -- Patronus Biotech, a biotechnology company that develops next-generation vaccines to address unmet global needs, today announced that its Phase I first-in-human clinical trial NCT07831226 of three novel multi-stage VLP-based investigational vaccine candidates for malaria has received ethical approval from Bellberry Limited on 19 October 2026. LYB014 targets 3 key stages of the Plasmodium...

New Innovative Molecular Technology Combination “LAMP + CRISPR” as CE-IVD

MUNICH, Oct. 20, 2026 /PRNewswire/ -- AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, "eazySNP" combines the highly specialized molecular technologies LAMP and CRISPR. By integrating these two methods, eazySNP enables the rapid and highly specific detection of genetic variants. This technological synergy was made possible through the scientific collaboration...

Colossal to Repatriate Rare Moa Egg to Aotearoa (New Zealand)

CHRISTCHURCH, New Zealand and DALLAS, Oct. 20, 2026 /PRNewswire/ -- Colossal Biosciences, the world's first de-extinction company, today announced that it has acquired a rare giant moa egg from a private collection in the United States for the sole purpose of returning it to Aotearoa (New Zealand). Colossal plans to present the egg to Professor Te Maire Tau (Ūpoko of Ngāi Tūāhuriri, a hapu of Ngāi Tahu), a distinguished Māori historian,...

Can we produce low-cost omega-3s without relying on fish?

GOLD COAST, Australia, Oct. 20, 2026 /PRNewswire/ -- Southern Cross University researchers are aiming to halve the cost of producing omega-3 supplements to make these essential nutrients more accessible to pregnant women and infants in low-income countries, backed by the University's first-ever grant from The Gates Foundation.The research takes a novel approach: rather than relying on fish oil, the team is going closer to the original source...

CHANDO Group Showcases Chinese Beauty Science at COSMETIC 360, Debuts Fatigue-Aging Research on Global Stage

PARIS, Oct. 19, 2026 /PRNewswire/ -- CHANDO Group featured its five brands and latest advances in cosmetic ingredient research at the 12th edition of COSMETIC 360, organized by Cosmetic Valley and held at the Louvre in Paris on October 14–15. As a representative of China's beauty industry, the Group also participated in the 2026 International Cosmetics Innovation Summit (INPD). At the event, CHANDO Group presented its findings on fatigue-...

UEG Week 2026: Antibiotic use from childhood linked to higher odds of IBS in young adulthood

BARCELONA, Spain, Oct. 19, 2026 /PRNewswire/ -- Antibiotic use from childhood through early adulthood is associated with higher odds of irritable bowel syndrome (IBS) at age 24, with the odds increasing as the number of antibiotic prescriptions rose, according to a new study presented today at UEG Week 2026.Researchers analysed data from 2,853 participants in the Swedish BAMSE birth cohort. Antibiotic prescriptions were obtained from the...

Stay up to date

On all things Queensland

Please wait...

Thank you for sign up!